Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 3 |
| List of Tables | 4 | 1 |
| List of Figures | 4 | 1 |
| Introduction | 5 | 1 |
| Global Markets Direct Report Coverage | 5 | 1 |
| Dilated Cardiomyopathy Overview | 6 | 1 |
| Therapeutics Development | 7 | 1 |
| Pipeline Products for Dilated Cardiomyopathy Overview | 7 | 1 |
| Dilated Cardiomyopathy Therapeutics under Development by Companies | 8 | 1 |
| Dilated Cardiomyopathy Pipeline Products Glance | 9 | 3 |
| Clinical Stage Products | 9 | 1 |
| Early Stage Products | 10 | 1 |
| Unknown Stage Products | 11 | 1 |
| Dilated Cardiomyopathy Products under Development by Companies | 12 | 1 |
| Dilated Cardiomyopathy Companies Involved in Therapeutics Development | 13 | 6 |
| Array BioPharma Inc. | 13 | 1 |
| Capricor Therapeutics, Inc. | 14 | 1 |
| Hemostemix Ltd | 15 | 1 |
| Kasiak Research Private Limited | 16 | 1 |
| Sanofi | 17 | 1 |
| Vericel Corporation | 18 | 1 |
| Dilated Cardiomyopathy Therapeutics Assessment | 19 | 9 |
| Assessment by Monotherapy Products | 19 | 1 |
| Assessment by Target | 20 | 2 |
| Assessment by Mechanism of Action | 22 | 2 |
| Assessment by Route of Administration | 24 | 2 |
| Assessment by Molecule Type | 26 | 2 |
| Drug Profiles | 28 | 21 |
| ACP-01 Drug Profile | 28 | 3 |
| ARRY-797 Drug Profile | 31 | 2 |
| CAP-1002 Drug Profile | 33 | 5 |
| CIP-137401 Drug Profile | 38 | 1 |
| Drugs for Dilated Cardiomyopathy Drug Profile | 39 | 1 |
| ixmyelocel-T Drug Profile | 40 | 7 |
| MYK-491 Drug Profile | 47 | 1 |
| Refacell-DCM Drug Profile | 48 | 1 |
| Dilated Cardiomyopathy Dormant Projects | 49 | 1 |
| Dilated Cardiomyopathy Product Development Milestones | 50 | 9 |
| Featured News &Press Releases | 50 | 1 |
| Apr 04, 2016: Results from Vericel Positive Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T Presented at ACC and Published in The Lancet | 50 | 1 |
| Mar 29, 2016: Vericel to Host Review of Positive Phase 2b ixCELL-DCM Trial Results Following American College of Cardiology 65th Annual Scientific Sessions | 51 | 1 |
| Mar 28, 2016: Vericel Announces Publication of Clinical Trial Rationale and Study Design for the Phase 2b ixCELL-DCM Trial of Ixmyelocel-T in Patients with Heart Failure Due to Ischemic Dilated Cardiomyopathy | 51 | 1 |
| Mar 10, 2016: Vericel Announces Positive Top-Line Results From Phase 2b ixCELL-DCM Clinical Trial of Ixmyelocel-T in Patients With Heart Failure Due to Ischemic Dilated Cardiomyopathy | 52 | 1 |
| Jan 29, 2015: Vericel Completes Patient Enrollment in Phase 2b ixCELL-DCM Clinical Study of Ixmyelocel-T | 53 | 1 |
| Dec 19, 2013: Aastrom Biosciences Granted Composition-of-Matter Patent for Ixmyelocel-T in Australia | 53 | 1 |
| Dec 17, 2013: Capricor Therapeutics Cleared to Begin Phase II Portion of ALLSTAR Clinical Trial with CAP-1002 in Patients Following Heart Attack | 53 | 1 |
| Apr 19, 2013: Aastrom Biosciences Announces First Patients Treated In IxCELL-DCM Clinical Study Of Ixmyelocel-T | 54 | 1 |
| Jun 06, 2012: Aastrom Presents Preclinical Data Of Ixmyelocel-T At 18th Annual International Society For Cellular Therapy Meeting | 54 | 1 |
| May 10, 2012: Treatment With Ixmyelocel-T Shows Improvement In Outcome Of Heart Failure Patients | 55 | 1 |
| May 07, 2012: Aastrom To Present Phase IIa Trial Results Of Ixmyelocel-T In Dilated Cardiomyopathy Patients At SCAI Scientific Sessions | 56 | 1 |
| Oct 03, 2011: Aastrom Receives European Composition-Of-Matter Patent For Ixmyelocel-T | 56 | 1 |
| Sep 19, 2011: Aastrom Announces Positive 12-Month Safety And Efficacy Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy | 57 | 1 |
| Sep 14, 2011: Aastrom To Present 12-Month Data From IMPACT-DCM Phase II Clinical Trial For Ixmyelocel-T In Treatment Of Dilated Cardiomyopathy | 58 | 1 |
| May 17, 2011: Aastrom To Present Results From Two Studies of Ixmyelocel-T At International Society For Cellular Therapy Meeting | 58 | 1 |
| Appendix | 59 | 2 |
| Methodology | 59 | 1 |
| Coverage | 59 | 1 |
| Secondary Research | 59 | 1 |
| Primary Research | 59 | 1 |
| Expert Panel Validation | 59 | 1 |
| Contact Us | 59 | 1 |
| Disclaimer | 60 | 1 |